$TBPH
Theravance Biopharma Inc

2019 Q4 Form 10-K Financial Statement

#000155837021002006 Filed on February 26, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $29.50M $12.43M $26.15M
YoY Change 87.45% -3.2% 11.39%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $29.50M $12.40M
YoY Change 95.36% 2.48%
Gross Profit Margin 100.0% 99.78%
Selling, General & Admin $33.00M $25.62M $22.23M
YoY Change 29.41% 17.05% -11.12%
% of Gross Profit 111.86% 206.63%
Research & Development $67.60M $52.01M $46.40M
YoY Change 29.25% -1.3% -4.57%
% of Gross Profit 229.15% 419.4%
Depreciation & Amortization $1.760M $1.810M $1.550M
YoY Change 104.65% 191.94% 96.2%
% of Gross Profit 5.97% 14.6%
Operating Expenses $100.1M $77.63M $68.63M
YoY Change 27.71% 3.11% -4.92%
Operating Profit -$70.57M -$65.20M -$42.48M
YoY Change 12.7% 4.41% -12.79%
Interest Expense $5.000M $8.068M $7.901M
YoY Change -45.65% 277.54% 269.72%
% of Operating Profit
Other Income/Expense, Net $2.089M $2.374M
YoY Change 51.82% 84.89%
Pretax Income -$65.60M -$63.98M -$39.64M
YoY Change 22.85% 6.48% -16.74%
Income Tax $0.00 -$5.552M $201.0K
% Of Pretax Income
Net Earnings -$65.61M -$58.43M -$39.84M
YoY Change 30.73% -1.69% -2.4%
Net Earnings / Revenue -222.4% -470.19% -152.34%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.169M -$1.045M -$717.1K
COMMON SHARES
Basic Shares Outstanding 56.76M 56.69M 56.41M
Diluted Shares Outstanding 55.86M 55.53M

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $280.8M $319.7M $396.1M
YoY Change -44.42% 6.42% 12.23%
Cash & Equivalents $58.06M $102.4M $178.3M
Short-Term Investments $222.8M $217.3M $217.8M
Other Short-Term Assets $7.100M $14.60M $8.900M
YoY Change -57.99% 100.0% 3.49%
Inventory
Prepaid Expenses
Receivables $12.00M $87.00K $111.0K
Other Receivables $38.60M $16.60M $20.00M
Total Short-Term Assets $338.5M $355.7M $426.0M
YoY Change -36.47% 6.93% 10.17%
LONG-TERM ASSETS
Property, Plant & Equipment $12.64M $12.19M $12.66M
YoY Change -4.04% -1.7% 18.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.000M $24.90M
YoY Change -57.98% 23.27%
Other Assets $1.590M $1.305M $1.388M
YoY Change 3.65% -49.81% -46.62%
Total Long-Term Assets $70.34M $89.69M $66.41M
YoY Change 156.6% 133.55% 91.38%
TOTAL ASSETS
Total Short-Term Assets $338.5M $355.7M $426.0M
Total Long-Term Assets $70.34M $89.69M $66.41M
Total Assets $408.8M $445.3M $492.4M
YoY Change -27.03% 20.04% 16.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.758M $8.713M $3.501M
YoY Change -47.3% 135.49% -2.75%
Accrued Expenses $65.50M $57.70M $51.00M
YoY Change 42.08% 40.73% 44.07%
Deferred Revenue $31.58M $33.75M $43.31M
YoY Change -27.25%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.900M $8.700M $12.30M
YoY Change
Total Short-Term Liabilities $111.7M $108.8M $110.1M
YoY Change 13.34% 6.69% 17.79%
LONG-TERM LIABILITIES
Long-Term Debt $445.2M $447.6M $443.1M
YoY Change -2.02% 99.29% 97.55%
Other Long-Term Liabilities $21.29M $8.900M $14.46M
YoY Change -14.03% -84.6% -79.11%
Total Long-Term Liabilities $21.29M $8.900M $14.46M
YoY Change -14.03% -96.85% -95.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $111.7M $108.8M $110.1M
Total Long-Term Liabilities $21.29M $8.900M $14.46M
Total Liabilities $133.0M $117.7M $124.6M
YoY Change 7.84% -69.37% -67.81%
SHAREHOLDERS EQUITY
Retained Earnings -$1.249B -$1.183B -$1.125B
YoY Change 23.36%
Common Stock $1.000K $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$223.8M -$182.8M -$137.2M
YoY Change
Total Liabilities & Shareholders Equity $408.8M $445.3M $492.4M
YoY Change -27.03% 20.04% 16.86%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$65.61M -$58.43M -$39.84M
YoY Change 30.73% -1.69% -2.4%
Depreciation, Depletion And Amortization $1.760M $1.810M $1.550M
YoY Change 104.65% 191.94% 96.2%
Cash From Operating Activities -$64.35M -$44.63M -$48.03M
YoY Change 23.32% -8.88% -21.95%
INVESTING ACTIVITIES
Capital Expenditures -$1.310M -$70.00K -$580.0K
YoY Change -12.67% -96.26% -47.27%
Acquisitions
YoY Change
Other Investing Activities $15.36M -$23.58M -$720.0K
YoY Change -84.78% -148.59% -101.67%
Cash From Investing Activities $14.06M -$23.65M -$1.300M
YoY Change -85.85% -150.7% -103.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.550M -130.0K 4.400M
YoY Change -100.68% -59.37% -283.33%
NET CHANGE
Cash From Operating Activities -64.35M -44.63M -48.03M
Cash From Investing Activities 14.06M -23.65M -1.300M
Cash From Financing Activities -1.550M -130.0K 4.400M
Net Change In Cash -51.84M -68.41M -44.93M
YoY Change -118.73% 2481.51% 104.41%
FREE CASH FLOW
Cash From Operating Activities -$64.35M -$44.63M -$48.03M
Capital Expenditures -$1.310M -$70.00K -$580.0K
Free Cash Flow -$63.04M -$44.56M -$47.45M
YoY Change 24.39% -5.41% -21.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57015000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64328000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseLiabilityNoncurrent
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001583107
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseRightOfUseAsset
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseRightOfUseAsset
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseLiabilityNoncurrent
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-36033
CY2020 dei Entity Registrant Name
EntityRegistrantName
THERAVANCE BIOPHARMA, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
KY
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1226628
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
P.O. Box 309
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Ugland House, South Church Street
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
George Town, Grand Cayman
CY2020 dei Entity Address Country
EntityAddressCountry
KY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
KY1-1104
CY2020 dei City Area Code
CityAreaCode
650
CY2020 dei Local Phone Number
LocalPhoneNumber
808-6000
CY2020 dei Security12b Title
Security12bTitle
Ordinary Share $0.00001 Par Value
CY2020 dei Trading Symbol
TradingSymbol
TBPH
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
1280000000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64327830
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81467000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58064000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
211474000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
222767000
CY2020Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
15868000
CY2019Q4 tbph Receivables From Collaboration Partners
ReceivablesFromCollaborationPartners
11996000
CY2019Q4 tbph Receivables From Licensing Arrangements
ReceivablesFromLicensingArrangements
10000000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
53799000
CY2019Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
28574000
CY2020Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
20374000
CY2019Q4 tbph Prepaid Clinical And Development Services
PrepaidClinicalAndDevelopmentServices
2736000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
10359000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4351000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
393341000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
338488000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16422000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12644000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4985000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43260000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46604000
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
12750000
CY2019Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
3682000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
833000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2451000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1590000
CY2020Q4 us-gaap Assets
Assets
469057000
CY2019Q4 us-gaap Assets
Assets
408826000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6775000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4758000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
35238000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28180000
CY2020Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
28799000
CY2019Q4 tbph Accrued Clinical And Development Expenses Current
AccruedClinicalAndDevelopmentExpensesCurrent
17587000
CY2020Q4 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
6048000
CY2019Q4 tbph Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
4394000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3974000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5659000
CY2020Q4 tbph Non Recourse Debt Due2035 Current
NonRecourseDebtDue2035Current
19334000
CY2019Q4 tbph Non Recourse Debt Due2033 Current
NonRecourseDebtDue2033Current
9851000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9867000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7762000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11523000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
31575000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2013000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1937000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
123571000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
111703000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
226963000
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
225890000
CY2020Q4 tbph Non Recourse Debt Due2035 Noncurrent
NonRecourseDebtDue2035Noncurrent
372873000
CY2019Q4 tbph Non Recourse Debt Noncurrent
NonRecourseDebtNoncurrent
219300000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
230000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
469057000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
408826000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47220000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47725000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
348000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6761000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1833000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21287000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64328000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57015000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1222818000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1024614000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
47000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
145000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1526617000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1248600000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71857000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73414000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60370000
CY2018 tbph Adjusted Cost Of Goods And Services Sold
AdjustedCostOfGoodsAndServicesSold
715000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
260953000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
219248000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
201348000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
108661000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
106081000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97058000
CY2020 us-gaap Operating Expenses
OperatingExpenses
369614000
CY2019 us-gaap Operating Expenses
OperatingExpenses
325329000
CY2018 us-gaap Operating Expenses
OperatingExpenses
299121000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-297757000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-251915000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-238751000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
68438000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
33705000
CY2018 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
11182000
CY2020 us-gaap Interest Expense
InterestExpense
44585000
CY2019 us-gaap Interest Expense
InterestExpense
31862000
CY2018 us-gaap Interest Expense
InterestExpense
10482000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2831000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8395000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11966000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-286537000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-241677000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-226085000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8520000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5222000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10561000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-278017000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-236455000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-215524000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.46
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.25
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.99
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62345000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55610000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53969000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62976000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60450000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51313000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-278017000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-236455000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-215524000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-98000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
311000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
567000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-278115000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-236144000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-214957000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
115178000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4173000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51313000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1393000
CY2018 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9808000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
567000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-215524000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-51589000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-51589000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3474000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60450000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3142000
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3173000
CY2020 tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1079000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
311000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-236455000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-223840000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
139915000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3701000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
62976000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1361000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
9749000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-98000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-278017000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-303751000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-278017000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-236455000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-215524000
CY2020 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
6798000
CY2019 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
6441000
CY2018 us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
4481000
CY2019 tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
3451000
CY2018 tbph Amortization And Accretion Income
AmortizationAndAccretionIncome
1315000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
62976000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
60450000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
51313000
CY2018 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
6056000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3344000
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3224000
CY2020 tbph Adjustments For Equity Method Investments
AdjustmentsForEquityMethodInvestments
37975000
CY2019 tbph Adjustments For Equity Method Investments
AdjustmentsForEquityMethodInvestments
23152000
CY2018 tbph Adjustments For Equity Method Investments
AdjustmentsForEquityMethodInvestments
5152000
CY2020 tbph Interest Shortfall On2035 Notes
InterestShortfallOn2035Notes
17643000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15464000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
95000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-146000
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
43000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-620000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1633000
CY2020 tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-6128000
CY2019 tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
11943000
CY2018 tbph Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
2944000
CY2020 tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
17638000
CY2019 tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
561000
CY2018 tbph Increase Decrease In Prepaid Clinical And Development Services
IncreaseDecreaseInPrepaidClinicalAndDevelopmentServices
2175000
CY2020 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2327000
CY2019 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
73000
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
225000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1629000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
258000
CY2019 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3700000
CY2018 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-8191000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
852000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
358000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-45000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3658000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4274000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3575000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5983000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10626000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12357000
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-1685000
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2573000
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1841000
CY2018 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-4308000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-26465000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31245000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
69224000
CY2020 tbph Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1600000
CY2019 tbph Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2317000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-7606000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-4748000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-10058000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-250403000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-238197000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112867000
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
6616000
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3176000
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
7240000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
401987000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
423898000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
183261000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
399318000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
339018000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
347192000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19942000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
64000
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
17000
CY2019 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
5000000
CY2018 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
20000000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10721000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83051000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
176708000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
139915000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
380000000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5326000
CY2018 tbph Proceeds From Issuance Of Non Recourse Debt
ProceedsFromIssuanceOfNonRecourseDebt
229441000
CY2020 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
11470000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
235347000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2152000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3701000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3474000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
4173000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1361000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3142000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1393000
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9749000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3173000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
9807000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
263085000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1291000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225200000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23403000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-319957000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
289041000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58897000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378854000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89813000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82300000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58897000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378854000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
24024000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
26178000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
7475000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
22000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-7316000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49847000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</p>
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Advertising Expense
AdvertisingExpense
2400000
CY2018 us-gaap Advertising Expense
AdvertisingExpense
1900000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
6300000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company invests in a variety of financial instruments and, based on its policy, limits the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the US federal government. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s receivables primarily relate to amounts due under its collaboration and licensing agreements. Accordingly, the Company may be exposed to credit risk generally associated with pharmaceutical companies or specific to its collaboration agreements. The Company performs periodic evaluations of its customers and generally does not require collateral. For the year ended December 31, 2020, 2019, and 2018, the Company did not experience any material losses related to its receivables.</p>
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
63400000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
58800000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-278017000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-236455000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-215524000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62808000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56452000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55076000
CY2020 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-463000
CY2019 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-842000
CY2018 tbph Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture Incremental Common Shares Attributable To Dilutive Effect Of Common Share Subject To Forfeiture
IncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeitureIncrementalCommonSharesAttributableToDilutiveEffectOfCommonShareSubjectToForfeiture
-1107000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62345000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55610000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53969000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.46
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.25
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.99
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274159000
CY2020 tbph Marketable Securities Maximum Contractual Maturity Period
MarketableSecuritiesMaximumContractualMaturityPeriod
P8M
CY2020 tbph Marketable Securities Average Contractual Maturity Period
MarketableSecuritiesAverageContractualMaturityPeriod
P3M
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13229000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13253000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10170000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
53000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
211474000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
274014000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
148000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020 tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
26464000
CY2019 tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
31245000
CY2018 tbph Collaborative Arrangements Revenue
CollaborativeArrangementsRevenue
130000
CY2018Q1 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.33
CY2020 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35
CY2020 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
10078000
CY2019 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
5589000
CY2018 tbph Collaborative Arrangement Research And Development Expenses Reimbursed To Entity
CollaborativeArrangementResearchAndDevelopmentExpensesReimbursedToEntity
9112000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
71857000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73414000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60370000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81467000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58064000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
378021000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
833000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
833000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
833000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82300000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58897000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
378854000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
211427000
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
44420000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
6000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
44420000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
6000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
33644000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
33644000
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3000
CY2020Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
0
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
19900000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
619170000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
455041000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
42625000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
28811000
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
9316000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1960000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3051000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1166000
CY2020 us-gaap Interest Expense
InterestExpense
44585000
CY2019 us-gaap Interest Expense
InterestExpense
31862000
CY2018 us-gaap Interest Expense
InterestExpense
10482000
CY2020Q4 tbph Area Of Leased Space
AreaOfLeasedSpace
170000
CY2020 tbph Number Of Building Leased
NumberOfBuildingLeased
2
CY2020Q4 tbph Tenant Improvement Allowance
TenantImprovementAllowance
12100000
CY2019Q4 tbph Tenant Improvement Allowance
TenantImprovementAllowance
15600000
CY2020 tbph Number Of Options To Extend
NumberOfOptionsToExtend
2
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43260000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46604000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9867000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7762000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47220000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47725000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
57087000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
55487000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
8732000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
8123000
CY2018 us-gaap Operating Lease Cost
OperatingLeaseCost
7985000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
3804000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
7210000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
10330000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10345000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10134000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
10351000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
10649000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
49309000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
101118000
CY2020Q4 tbph Tenant Improvement Allowance
TenantImprovementAllowance
12053000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
31978000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
57087000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0864
CY2020Q4 us-gaap Equity Method Investments
EquityMethodInvestments
12800000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
62230000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
60212000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45808000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
47568000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16422000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12644000
CY2020 us-gaap Depreciation
Depreciation
3300000
CY2019 us-gaap Depreciation
Depreciation
3300000
CY2018 us-gaap Depreciation
Depreciation
3000000.0
CY2014Q2 tbph Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
3
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62976000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60450000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51313000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-8520000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-5222000
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-10561000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62976000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60450000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51313000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
114725000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.53
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-286537000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-241677000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-226085000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8520000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5222000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10561000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0297
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0216
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0467
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8500000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5200000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10600000
CY2020Q4 us-gaap Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries
DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
0
CY2020Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
82821000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
58161000
CY2020Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
19409000
CY2019Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
19409000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
24075000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15723000
CY2020Q4 tbph Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
310187000
CY2019Q4 tbph Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
285341000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
15087000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
15480000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
8145000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
8245000
CY2020Q4 tbph Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
11662000
CY2019Q4 tbph Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
11358000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
346000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
7000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
471732000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
413724000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
462711000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
403836000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9021000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9888000
CY2020Q4 tbph Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
8680000
CY2019Q4 tbph Deferred Tax Liabilities Operating Lease Assets
DeferredTaxLiabilitiesOperatingLeaseAssets
9429000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
341000
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
459000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9021000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9888000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
403800000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
462700000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
52404000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
2010000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
8369000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
58763000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
8059000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
12743000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
63447000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
63400000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
58800000
CY2019Q4 tbph Guarantees And Indemnifications Liability
GuaranteesAndIndemnificationsLiability
0
CY2020Q4 tbph Guarantees And Indemnifications Liability
GuaranteesAndIndemnificationsLiability
0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5500000
CY2020Q1 us-gaap Share Price
SharePrice
27.00
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
148500000
CY2019Q1 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
51
CY2019 us-gaap Severance Costs1
SeveranceCosts1
3500000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19862000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15008000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18257000
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18730000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
92338000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
87184000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
94872000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
95220000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-72476000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-72176000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-76615000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-76490000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-83053000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-62887000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-73643000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-58434000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.16
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5338000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26150000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12427000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29499000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
79004000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
68626000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
77628000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
100071000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-73666000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42476000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65201000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-70572000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-72580000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-39838000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-58431000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-65606000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.32
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2020 tbph Profit Loss Percentage As Per Collaboration Agreement
ProfitLossPercentageAsPerCollaborationAgreement
0.35

Files In Submission

Name View Source Status
0001558370-21-002006-index-headers.html Edgar Link pending
0001558370-21-002006-index.html Edgar Link pending
0001558370-21-002006.txt Edgar Link pending
0001558370-21-002006-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbph-20201231.xsd Edgar Link pending
tbph-20201231x10k.htm Edgar Link pending
tbph-20201231x10k006.jpg Edgar Link pending
tbph-20201231x10k008.jpg Edgar Link pending
tbph-20201231x10k_htm.xml Edgar Link completed
tbph-20201231xex10d51.htm Edgar Link pending
tbph-20201231xex10d51080.jpg Edgar Link pending
tbph-20201231xex10d60.htm Edgar Link pending
tbph-20201231xex10d60001.jpg Edgar Link pending
tbph-20201231xex21d1.htm Edgar Link pending
tbph-20201231xex23d1.htm Edgar Link pending
tbph-20201231xex31d1.htm Edgar Link pending
tbph-20201231xex31d2.htm Edgar Link pending
tbph-20201231xex32.htm Edgar Link pending
tbph-20201231_cal.xml Edgar Link unprocessable
tbph-20201231_def.xml Edgar Link unprocessable
tbph-20201231_lab.xml Edgar Link unprocessable
tbph-20201231_pre.xml Edgar Link unprocessable